Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: James Perry who wrote (412)	8/21/1998 8:25:00 PM
From: John Zwiener	Read Replies (2) \| Respond to of 1025

No problem James, but I would not touch that one for now. Now Igen, I have been thinking why do I think this company is worth something? It occurs to me I still have been thinking of this as a company with no real products on much of a scale. I have adjusted for the progress made on many fronts, but my basic thinking was still stuck back when Igen was 5. But Igen has technology in over 6,000 instruments by Roche as of May 30 and there is reason to believe it was substantially higher at that time. There is probably over 7,000 instruments now. These are 9% royalty agreements for all instrument and reagent sales, income on an ongoing basis. There is almost no doubt that sales have been underreported by over 75%. Igen would be profitable today if sales were accurately reported. Either Roche will buyout the license soon, or they will have dirty laundry dragged out in court proving the deception IMO. (Actually, this is the fault of Boehringer Mannheim, Roche just bought into it when they acquired BM. Now we are approaching the time of reckoning, and longterm I still think there is no way these instruments are only doing $15,000 in revenue as is essentially being reported---it should be around $80,000 to 100,000 average. Any drop in Igen from here will cause me to accumualte more as usual. POC could happen anytime. Buyout of license could happen sooner than we think. High thruput shows excellent signs of being a future success, and it's progress reminds me of electsys's early days. Food and water testing looks better than I would have anticipated at this point. Other applications are in negotiation. When news comes, it could be big, even if the market is having a bad day. This company seems to be on the cusp of major revenues, and it won't take much to make a difference with the few numbers of shares out there.